Arthur Grider

Arthur Grider


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
JZJINGQI ZHOU
JINGQI ZHOU
CLC. Liu
C. Liu
YSYitang Sun
Yitang Sun
MFM. Francis
M. Francis
Moon-Suhn RyuMoon-Suhn Ryu
Moon-Suhn Ryu
Kaixiong YeKaixiong Ye
Kaixiong Ye

17 October 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
JZJINGQI ZHOU
JINGQI ZHOU
CLChang Liu
Chang Liu
MFMichael Francis
Michael Francis
YSYitang Sun
Yitang Sun
Moon-Suhn RyuMoon-Suhn Ryu
Moon-Suhn Ryu
Kaixiong YeKaixiong Ye
Kaixiong Ye
Blood levels of iron and copper, even within their normal ranges, have been associated with a wide range of clinical outcomes. The available epidemiological evidence for these associations is often inconsistent and suffers from confounding and reverse causation. This study aims to examine the causal clinical effects of blood iron and copper with Mendelian randomization (MR) analyses. Genetic instruments for the blood levels of iron and copper were curated from existing genome-wide association studies. Candidate clinical outcomes were identified based on a phenome-wide association study (PheWAS) between these genetic instruments and a wide range of phenotypes in 310,999 unrelated individuals of European ancestry from the UK Biobank. All signals passing stringent correction for multiple testing were followed by MR analyses, with replication in independent data sources where possible. We found that genetically predicted higher blood levels of iron and copper are both associated with lower risks of iron deficiency anemia (odds ratio (OR) = 0.75, 95% confidence interval (CI): 0.67–0.85, p = 1.90 × 10−6 for iron; OR = 0.88, 95% CI: 0.78–0.98, p = 0.032 for copper), lipid metabolism disorders, and its two subcategories, hyperlipidemia (OR = 0.90, 95% CI: 0.85–0.96, p = 6.44 × 10−4; OR = 0.92, 95% CI: 0.87–0.98, p = 5.51 × 10−3) and hypercholesterolemia (OR = 0.90, 95% CI: 0.84–0.95, p = 5.34 × 10−4; OR = 0.93, 95% CI: 0.89–0.99, p = 0.022). Consistently, they are also associated with lower blood levels of total cholesterol and low-density lipoprotein cholesterol. Multiple sensitivity tests were applied to assess the presence of pleiotropy and the robustness of causal estimates. Regardless of the approaches, consistent evidence was obtained. Moreover, the unique clinical effects of each blood mineral were identified. Notably, genetically predicated higher blood iron is associated with an enhanced risk of varicose veins (OR = 1.28, 95% CI: 1.15–1.42, p = 4.34 × 10−6), while blood copper is positively associated with the risk of osteoarthrosis (OR = 1.07, 95% CI: 1.02–1.13, p = 0.010). Sex-stratified MR analysis further revealed some degree of sex differences in their clinical effects. Our comparative PheWAS-MR study of iron and copper comprehensively characterized their shared and unique clinical effects, highlighting their potential causal roles in hyperlipidemia and hypercholesterolemia. Given the modifiable nature of blood mineral status and the potential for clinical intervention, these findings warrant further investigation.



22 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
JZJINGQI ZHOU
JINGQI ZHOU
CLChang Liu
Chang Liu
MFMichael Francis
Michael Francis
YSYitang Sun
Yitang Sun
Moon-Suhn RyuMoon-Suhn Ryu
Moon-Suhn Ryu
Kaixiong YeKaixiong Ye
Kaixiong Ye
Background: Blood levels of iron and copper, even within their normal ranges, have been associated with a wide range of clinical outcomes. Available epidemiological evidence on blood iron and copper association with potential clinical effects, such as lipid metabolism disorder, is inconsistent and scarce. This study aims to examine and disentangle the causal clinical effects of iron and copper. Methods: Genetic instruments for the blood level of iron and copper were curated from existing genome-wide association studies. Candidate clinical outcomes were identified based on a phenome-wide association study (PheWAS) between these genetic instruments and multiple phenotypes in 310,999 unrelated individuals of European ancestry from the UK Biobank. All signals passing stringent correction for multiple testing were followed by Mendelian randomization (MR) analyses, with replication in independent data sources where possible. Results: Genetically predicted higher blood levels of iron and copper are both associated with lower risks of iron deficiency anemia (OR = 0.75, 95% CI:0.67-0.85, p =1.90×10 −06 for iron; OR= 0.88, 95% CI: 0.78-0.98, p =0.03 for cooper), lipid metabolism disorders and its two subcategories, hyperlipidemia (OR = 0.90, 95% CI:0.85-0.96, p =6.44×10 −04 for iron; OR = 0.92, 95% CI:0.87-0.98, p = 5.51×10 −03 for cooper) and hypercholesterolemia (OR = 0.90, 95% CI:0.84-0.95, p = 5.34×10 −04 for iron; OR = 0.93, 95% CI:0.89–0.99, p =0.02 for cooper). Consistently, they are also associated with lower blood levels of total cholesterol and low-density lipoprotein cholesterol. Multiple sensitivity tests were applied to assess the pleiotropy and stability of the estimation, and consistent evidence across different approaches was obtained. Additionally, unique clinical effects of each blood mineral were also pinpointed, and sex-stratified MR analysis further revealed the clinical implication of iron and copper exhibits some degree of sex differences. Conclusions: Our comparative PheWAS-MR study of iron and copper comprehensively characterized their shared and unique clinical effects, highlighting their novel causal roles in hyperlipidemia and hypercholesterolemia. Given the modifiable and variable nature of blood mineral status, these findings warrant further investigation.

26 September 2015 in BioMetals
Verified
Journal Article
Closed access
PDF file
AGArthur Grider
Arthur Grider
RLRichard D. Lewis
Richard D. Lewis
ELEmma M. Laing
Emma M. Laing
Abhijeet BakreAbhijeet Bakre
Abhijeet Bakre
RTRalph A. Tripp
Ralph A. Tripp